EA201290822A1 - Триазолоны в качестве ингибиторов синтазы жирных кислот - Google Patents

Триазолоны в качестве ингибиторов синтазы жирных кислот

Info

Publication number
EA201290822A1
EA201290822A1 EA201290822A EA201290822A EA201290822A1 EA 201290822 A1 EA201290822 A1 EA 201290822A1 EA 201290822 A EA201290822 A EA 201290822A EA 201290822 A EA201290822 A EA 201290822A EA 201290822 A1 EA201290822 A1 EA 201290822A1
Authority
EA
Eurasian Patent Office
Prior art keywords
triazolones
fatty acids
synthase inhibitors
acids synthase
relates
Prior art date
Application number
EA201290822A
Other languages
English (en)
Russian (ru)
Inventor
Николас Д. Адамс
Кристофер Джозеф Аквино
Амита М. Чаудхари
Джонатан М. Гергурович
Теренс Джон Кисоу
Синтия А. Пэрриш
Александр Джозеф Райф
Кеннет Уиггалл
Original Assignee
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЛЭКСОСМИТКЛАЙН ЭлЭлСи filed Critical ГЛЭКСОСМИТКЛАЙН ЭлЭлСи
Publication of EA201290822A1 publication Critical patent/EA201290822A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201290822A 2010-02-22 2011-02-22 Триазолоны в качестве ингибиторов синтазы жирных кислот EA201290822A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30670910P 2010-02-22 2010-02-22
US35758710P 2010-06-23 2010-06-23
PCT/US2011/025661 WO2011103546A1 (en) 2010-02-22 2011-02-22 Triazolones as fatty acid synthase inhibitors

Publications (1)

Publication Number Publication Date
EA201290822A1 true EA201290822A1 (ru) 2013-03-29

Family

ID=44483349

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290822A EA201290822A1 (ru) 2010-02-22 2011-02-22 Триазолоны в качестве ингибиторов синтазы жирных кислот

Country Status (13)

Country Link
US (2) US8802864B2 (https=)
EP (1) EP2538787B1 (https=)
JP (1) JP5805672B2 (https=)
KR (1) KR20120133386A (https=)
CN (1) CN102858175A (https=)
AU (1) AU2011217809A1 (https=)
BR (1) BR112012020976A2 (https=)
CA (1) CA2790692A1 (https=)
EA (1) EA201290822A1 (https=)
ES (1) ES2509951T3 (https=)
MX (1) MX2012009720A (https=)
SG (1) SG183260A1 (https=)
WO (1) WO2011103546A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2509951T3 (es) * 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos
EP2822931B1 (en) * 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
SG11201504622PA (en) 2012-12-20 2015-07-30 Inception 2 Inc Triazolone compounds and uses thereof
US20150329524A1 (en) * 2013-01-10 2015-11-19 Glaxosmithkline Intellectual Property (No.2) Limited Fatty acid synthase inhibitors
ES2753386T3 (es) 2013-03-13 2020-04-08 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
JP6434522B2 (ja) 2013-09-05 2018-12-05 ダウ アグロサイエンシィズ エルエルシー ホウ素化アレーンを生成する方法
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
WO2015095011A1 (en) 2013-12-17 2015-06-25 Janssen Pharmaceutica Nv Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
TW201625354A (zh) 2014-06-16 2016-07-16 陶氏農業科學公司 用於製備氧硼基化芳烴之方法
CN104876917B (zh) * 2015-06-16 2017-09-19 上海皓元医药股份有限公司 用作脂肪酸合成酶抑制剂的三唑酮的合成方法
WO2016205590A1 (en) 2015-06-18 2016-12-22 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
KR20180026459A (ko) 2015-06-18 2018-03-12 세파론, 인코포레이티드 1,4-치환된 피페리딘 유도체
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN114539193B (zh) * 2022-01-20 2024-08-06 安徽普利药业有限公司 一种盐酸胺碘酮中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728834A (en) * 1996-11-14 1998-03-17 Wyckoff Chemical Company, Inc. Process for preparation of 4-aryl-1,2,4-triazol-3-ones
ATE552236T1 (de) * 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
SE0400850D0 (sv) * 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
ES2355923T3 (es) * 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
US8236792B2 (en) 2008-05-23 2012-08-07 Janssen Pharmaceutica Nv Substituted pyrrolidine amides as modulators of the histamine H3 receptor
ES2509951T3 (es) * 2010-02-22 2014-10-20 Glaxosmithkline Llc Triazolonas como inhibidores de sintasa de ácidos grasos

Also Published As

Publication number Publication date
US8802864B2 (en) 2014-08-12
CN102858175A (zh) 2013-01-02
ES2509951T3 (es) 2014-10-20
US20120316151A1 (en) 2012-12-13
US9340529B2 (en) 2016-05-17
JP5805672B2 (ja) 2015-11-04
CA2790692A1 (en) 2011-08-25
US20140100213A1 (en) 2014-04-10
JP2013520443A (ja) 2013-06-06
EP2538787A4 (en) 2013-07-17
BR112012020976A2 (pt) 2017-05-09
MX2012009720A (es) 2012-10-09
SG183260A1 (en) 2012-09-27
KR20120133386A (ko) 2012-12-10
EP2538787A1 (en) 2013-01-02
WO2011103546A1 (en) 2011-08-25
AU2011217809A1 (en) 2012-09-06
EP2538787B1 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
EA201290822A1 (ru) Триазолоны в качестве ингибиторов синтазы жирных кислот
WO2012037299A3 (en) Fatty acid synthase inhibitors
WO2012096928A3 (en) Pyrimidinone derivatives as fatty acid synthase inhibitors
PH12012502485A1 (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
PH12017502141A1 (en) Compounds and their methods of use
CA2871471C (en) Dna-pk inhibitors
EP2615918A4 (en) INHIBITORS OF ACID GRAS SYNTHASE
GEP20156229B (en) 5-alkynyl-pyrimidines
NZ724002A (en) Liquid formulation comprising propylene glycol and an ace inhibitor
IL223201A (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
WO2012135113A3 (en) Cyclopropylamines as lsd1 inhibitors
WO2012104007A3 (de) 7-azaindolderivate
MX2014003376A (es) Derivados de acido benzoico como inhibidores eif4e.
WO2013003298A3 (en) Inhibitors of pde10
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UA111198C2 (uk) Похідні 1-феніл-2-піридинілалкільних спиртів як інгібітори фосфодіестерази
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
EA201590744A1 (ru) Лечение рака tor киназными ингибиторами
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
EA201100615A1 (ru) Производные салициловой кислоты в качестве ингибиторов активности фарнезилпирофосфатсинтазы
IN2014DN08443A (https=)
WO2011103028A3 (en) Compositions and methods for inhibiting mmset
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.